Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and CAMBRIDGE, Mass., Sept. 10, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming virtual investor conferences:
马萨诸塞州剑桥，2024年9月10日 /PRNewswire/ — Blueprint Medicines Corporation（纳斯达克股票代码：BPMC）今天宣布将参加以下即将举行的虚拟投资者会议：
- Stifel 2024 Immunology and Inflammation Virtual Summit on Tuesday, September 17, 2024, at 2:00 p.m. ET.
- TD Cowen's Chronic Urticaria Summit on Friday, September 20, 2024, at 11:00 a.m. ET.
- Stifel 2024 免疫学和炎症虚拟峰会将于 2024 年 9 月 17 日星期二美国东部时间下午 2:00 举行。
- TD Cowen的慢性荨麻疹峰会将于美国东部时间2024年9月20日星期五上午11点举行。
A live webcast of each presentation will be available by visiting the Investors & Media section of Blueprint Medicines' website at . A replay of the webcasts will be archived on Blueprint Medicines' website for 30 days following each presentation.
每场演讲的网络直播将通过访问Blueprint Medicines网站的 “投资者与媒体” 栏目进行直播，网址为。每次演讲结束后，网络直播的重播将在Blueprint Medicines的网站上存档30天。
About Blueprint Medicines
关于蓝图药物
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT/AYVAKYT (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the U.S. and Europe. Leveraging our established research, development, and commercial capability and infrastructure, we now aim to significantly scale our impact by advancing a broad pipeline of programs ranging from early science to advanced clinical trials in mast cell diseases including SM and chronic urticaria, breast cancer and other solid tumors. For more information, visit and follow us on X (formerly Twitter; @BlueprintMeds) and LinkedIn.
Blueprint Medicines是一家全球性、完全整合的生物制药公司，致力于发明改变生活的药物。我们寻求通过解决两个核心重点领域的重要医疗问题来减轻人类痛苦：过敏/炎症和肿瘤学/血液学。我们的方法首先是针对疾病的根本原因，运用我们核心重点领域的深厚科学知识和跨多种治疗模式的药物研发专业知识。我们在两种获批药物方面有着良好的成功记录，其中包括我们为美国和欧洲的系统性肥大细胞增多症（SM）患者提供的Ayvakit/Ayvakyt（阿伐替尼）。利用我们既有的研究、开发、商业能力和基础设施，我们现在的目标是通过推进从早期科学到包括Sm和慢性荨麻疹、乳腺癌和其他实体瘤在内的肥大细胞疾病的高级临床试验等广泛项目来显著扩大我们的影响力。欲了解更多信息，请在 X（前身为 Twitter；@BlueprintMeds）和 LinkedIn 上访问并关注我们。
SOURCE Blueprint Medicines Corporation
来源蓝图药品公司